Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ: BIOA )

18.80 -0.49 (-2.54%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 97,054
Open 19.30
Bid (Size) 18.00 (5)
Ask (Size) 20.00 (17)
Prev. Close 19.29
Today's Range 18.78 - 19.53
52wk Range 18.00 - 26.62
Shares Outstanding 129,450,655
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire

Performance

YTD
+2.68%
+2.68%
1 Month
-20.34%
-20.34%
3 Month
+2.68%
+2.68%
6 Month
+2.68%
+2.68%
1 Year
+2.68%
+2.68%

More News

Read More
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs to Present at Jefferies London Healthcare Conference
From BioAge Labs, Inc.
Via GlobeNewswire
Self-Driving Startup Pony.ai Files For U.S. IPO
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Prediction: These 2 Stocks Could Soar in 2025
Via The Motley Fool
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
Via The Motley Fool
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
Via The Motley Fool
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October
Via The Motley Fool
This IPO Biotech Stock Could Be the Next Eli Lilly
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
From BioAge Labs, Inc.
Via GlobeNewswire
Obesity Drug Developer BioAge Makes Nasdaq Debut
Via Talk Markets
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.